Loading Curie Briefs...
Getting the latest healthcare news for you
Getting the latest healthcare news for you
The SINGLE-AF trial is the first randomized study to show that direct oral anticoagulants (DOACs) reduce cardiovascular events in atrial fibrillation patients with just one stroke risk factor — without a significant increase in major bleeding. The composite event rate was 0.5% with DOACs vs. 1.5% without anticoagulation. Experts call the findings promising but not yet practice-changing, given the low event counts and limited generalizability.
For years, the question of whether to prescribe blood thinners to lower-risk atrial fibrillation (AFib) patients has been a clinical gray zone. Now, the SINGLE-AF trial — the first randomized controlled trial of its kind — offers some clarity. Presented at the European Society of Cardiology Congress 2026 and published simultaneously in the New England Journal of Medicine, the trial found that DOAC therapy reduced a composite of stroke, systemic embolism, major bleeding, and cardiovascular death by 69% compared to no anticoagulation in AFib patients with just one CHA₂DS₂-VASc risk factor.
The trial enrolled 1,803 patients in South Korea, randomizing them to a DOAC (mostly apixaban) or no anticoagulation over a median follow-up of 730 days. While the relative benefit was striking, experts urge caution — only 17 total primary endpoint events occurred, meaning the true magnitude of benefit remains uncertain. Generalizability is also limited, as the cohort was entirely East Asian, predominantly male, and relatively young.
Key Takeaways:
Why it matters: Current U.S. guidelines only give a modest Class IIa recommendation for DOACs in intermediate-risk AFib patients. SINGLE-AF is the first RCT to support that recommendation, potentially reshaping shared decision-making conversations — though larger, more diverse confirmatory trials are still needed.
